microbiome

Developing a range of products to modify the human
microbiome and bring specific health benefits

RNS & Investor News


2017

14 December Exercise of warrant and issue of equity
12 December SlimBiome® USA manufacturing, supply and profit sharing agreement
05 December Proposed directorate changes
28 November Capital reorganisation: Potential for future dividend payments
17 November Exercise of Warrant and Issue of Equity
08 November SlimBiome® commercial and product development update
02 November Rapidly Transitioning to Commercial Phase
Capital Network Report (pdf)
01 November Manufacturing, supply and profit sharing agreement with Knighton Foods
26 October Presentation of research at MicroBiome R&D and Business Collaboration: USA
24 October LPLDL® supply agreement with Galenicum
04 October Successful launch of LPLDL® and SlimBiome® products at Supply Side West 2017
19 September SlimBiome®: Technical, Regulatory and Commercial Update
13 September Strategic partnership with Bened Biomedical
11 September Holding(s) in Company
07 September OptiBiotix invited to present at Expoquimia in Barcelona
06 September Investor evening
05 September Scale up and Manufacturing Agreement with Tata Chemicals
01 September Exercise of Option and Issue of Equity
30 August Half Yearly Report
24 August US product launch of LPLDL® at Supply Side West trade show
22 August Global manufacturing and supply agreement with Sacco S.r.l.
31 July Total Voting Rights
26 July Market launch for LPLDL® capsules in Germany
17 July LPLDL® supply agreement for New Zealand & Australia with Pharmabiota Ltd
11 July SweetBiotix® development: Results of human taste study
06 July Grant of Options
15 June Result of AGM
15 June Supply agreement for LPLDL® capsules with HLH Biopharma GmbH
31 May Holding(s) in Company
16 May Successful Launch of LPLDL® and SlimBiome® products at Vitafoods 2017
09 May LPLDL® Non-Exclusive European License Agreement
03 May Presentation of abstract at Probiotics and Prebiotics conference
25 April First sales of LPLDL® to German market
25 April Final Results
Notice of AGM
04 April Notice of Results, Analyst and Investor Briefing
29 March UK Investor Show attendance
24 March Holding(s) in Company
21 March Intention to float SkinBiotherapeutics
15 March Confirmation of Director appointments to the Board
08 March European manufacturing, supply and profit sharing agreement
01 March Launch of products at Vitafoods 2017
08 February Exercise of Warrants and Issue of Equity
26 January Result of General Meetings of Warrant Holders
18 January Appointment of Sales and Marketing Director
17 January Holding(s) in Company
13 January Exercise of Option and Issue of Equity
11 January Exercise of Warrants and Issue of Equity
05 January Appointment of New Commercial Director
03 January Increased investment in The Healthy Weight Loss Company Ltd

 

Presentations/Interviews

In the Media

Latest Tweets Twitter

top